Evaluation of a new diagnostic technology for tuberculous pleurisy: a multicenter study

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000031680

Enrollment

Unknown

Registered

2020-04-06

Start date

2020-05-26

Completion date

Unknown

Last updated

2023-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculous pleurisy

Interventions

Gold Standard:Mycobacterium culture or genexpert of pleural effusion or pleural tissue

Index test:Detection of MTB cfDNA

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Those patients with pleural effusion indicated by imaging examination should be considered as tuberculous pleurisy; 2. Patients with indications of thoracentesis and expected collection volume of pleural effusion not less than 100 ml; 3. Patients with informed consent and voluntary subjects (children under the age of 18 need the signature of legal guardian at the same time).

Exclusion criteria

Exclusion criteria: 1. Patients who have started anti tuberculosis treatment for more than one week; 2. Patients who are not suitable for the study according to the actual situation.

Design outcomes

Primary

Measure	Time frame
MTB cfDNA;protein, LDH, ADA;Mycobacterium tuberculosis complex;MTB specific gene;	—

Countries

China

Contacts

Public ContactNanying Che

Beijing Chest Hospital Affiliated to Capital Medical University

cheny0448@163.com+86 10-89509381

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026